The Zephyr Endobronchial Valve is an endoscopic lung volume reduction therapy designed to significantly improve lung function, exercise capacity and quality of life for emphysema patients. It has been studied in four randomized, controlled clinical trials and has been used to treat 12,000 patients outside of the United States.
Pulmonx has also developed an assessment product – the Chartis Pulmonary Assessment System – that is designed to identify likely responders and non-responders to Zephyr valve therapy in order to improve patient outcomes.
The Zephyr valve is also designed to be removable, preserving future treatment options for patients.
A US pivotal trial of the Zephyr valve – the LIBERATE Trial – has been undertaken and will be used as part of the company’s submission to the FDA to obtain US marketing approval.
Once implanted, the one-way valve prevents airflow into the diseased region, while allowing trapped air and fluids to escape.
Reducing the volume of the diseased region may allow healthier regions to expand and function more efficiently.
CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.